Divya Natesan, Li Zhang, Henry J Martell, Tanya Jindal, Patrick Devine, Bradley Stohr, Carlos Espinosa-Mendez, James Grenert, Jessica Van Ziffle, Nancy Joseph, Sarah Umetsu, Courtney Onodera, Michelle Turski, Emily Chan, Arpita Desai, Rahul Aggarwal, Anthony Wong, Sima Porten, Jonathan Chou, Terence Friedlander, Lawrence Fong, Eric J Small, Alejandro Sweet-Cordero, Vadim S Koshkin
Introduction: Tumor mutational burden (TMB) and APOBEC mutational signatures are potential prognostic markers in patients with advanced urothelial carcinoma (aUC). Their utility in predicting outcomes to specific therapies in aUC warrants additional study. Methods: We retrospectively reviewed consecutive UC cases assessed with UCSF500, an institutional assay that uses hybrid capture enrichment of target DNA to interrogate 479 common cancer genes. Hypermutated tumors (HM), defined as having TMB ≥10 mutations/Mb, were also assessed for APOBEC mutational signatures, while non-HM (NHM) tumors were not assessed due to low TMB...
2022: Frontiers in Oncology